Gastric Cancer Awareness Month
Prevention and early detection matters
Biohit invites EU policymakers and stakeholders to the GastroPanel® Demo Day in Brussels.
Dates: 10th and 11th November
Time: 10:00-17:00
Location: Nordic Spaces Palmerston: Avenue Palmerston 3, 1000 Brussels
The event is by invitation only. You are welcome to come at any time between 10:00 and 17:00 on either day, or you can book a timeslot in advance.
Why early detection and prevention are crucial
Gastrointestinal health faces growing challenges worldwide, driven by an aging population and limited healthcare resources. In addition, the increasing prevalence of gastrointestinal disorders underscores the urgent need for innovative solutions and improved care strategies.
Gastric cancer often causes common, non-specific symptoms, which can delay diagnosis and treatment. As a result, it is frequently detected at an advanced stage, when survival is low and treatment costs are high. Early detection improves the chances of survival and reduces treatment costs.
Screening must be in place in high-incidence regions, such as Eastern Europe, the Baltics and Portugal, as recommended by the Council of the European Union in 2022 (1).
GastroPanel is a non-invasive blood test that enables the early detection of precancerous gastric conditions, before they progress to cancer. By identifying at-risk patients earlier, it can help save lives through timely intervention and better outcomes, while also reducing healthcare costs associated with advanced cancer treatment.
A timely moment for gastric cancer screening
Europe’s Beating Cancer Plan: recent developments in the EU’s cancer strategy have increased attention to cancer screening and prevention.
European Parliament SANT Committee: the Committee has called for stronger alignment of national screening practices with EU recommendations, including greater attention to gastric cancer.
Gastric Cancer Awareness Month: November provides a timely opportunity to raise awareness.
What the Demo Day offers
Discover how GastroPanel can help identify patients at increased risk of gastric cancer.
See how the test works in practice, from sample collection to results and interpretation.
Explore how GastroPanel could support risk-based screening strategies and more efficient use of healthcare resources.
Discuss the potential benefits of earlier detection for patient outcomes and healthcare costs.
1. Council Recommendation of 9 December 2022 on strengthening prevention through early detection: A new EU approach on cancer screening replacing Council Recommendation 2003/878/EC (2022/C 473/01). Official Journal of the European Union, C 473, 13.12.2022, p. 1–10. Publications Office of the EU